参考文献
1. Hsueh PR., et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004 Dec;10(12):1062-6.
2. Lee N., et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J Clin Virol. 2006 Feb;35(2):179-84.
3. Wu LP., et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007 Oct;13(10):1562-4.
4. Tang F., et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011 Jun 15;186(12):7264-8.
5. Wang H., et al. Follow-up study on serological detection of anti-SARS-CoV IgG/IgM antibody and its significance. Infectious Disease Information 2009:235-7.
6. Guo X., et al. Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers. MedRxiv 2020.02.12.20021386.
7. Park WB., et al. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea. Emerg Infect Dis. 2015 Dec;21(12):2186-9.
8. Choe PG., et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis. 2017 Jul;23(7):1079-1084.
9. Payne DC., et al. Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg Infect Dis. 2016 Oct;22(10):1824-6.
10. Adams ER., et al. Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. MedRxiv 2020.04.15.20066407.
11. Long QX., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-848.
12. Robbiani DF., et al. Convergent antibody responses to SARS- CoV-2 in convalescent individuals. Nature. 2020 Jun 18.
13. Staines HM., et al. Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections. MedRxiv 2020.06.07.20124636.
14. Seow J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. MedRxiv 2020.07.09.20148429.
15. Wang K., et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. MedRxiv 2020.07.14.20151159.
16. Perreault J., et al. Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors. BioRxiv 2020.07.16.206847.
17. Wajnberg A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. MedRxiv 2020.07.14.20151126.
18. Ibarrondo FJ., et al. Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. NEJM. 2020; (published online July 21.)
19. Lyer AS., et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. MedRxiv 2020.07.18.20155374.
20. Grandjean L., et al. Humoral Response Dynamics Following Infection with SARS-CoV-2. MedRxiv 2020.07.16.20155663.
21. Yao XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. MedRxiv 2020.07.18.20156810.
22. Wu J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. MedRxiv 2020.7.21.20159178.
23. Zhu FC., et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; (published online July 20.)
24. Folegatti PM., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; (published online July 20.)
25. Juno JA., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; (published online July 13..)
26. Bert NL., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature.2020; (published online July 15.)
联系客服
